News Gilead's twice-yearly HIV PrEP set for wider rollout The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.
News Just how radical is the FDA's complete response letter move? The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.
News UK authority cracks down on weight-loss drug ads Nine adverts for weight-loss services have been banned by the Advertising Standards Authority in the UK for promoting prescription-only drugs.
News Novo Nordisk files high-dose Wegovy in EU Novo Nordisk has moved quickly to file for approval of a higher-dose version of obesity drug Wegovy as it fends off stiff competition from Eli Lilly.
News J&J bids to extend prostate cancer uses for Akeega J&J is hoping the AMPLITUDE study results will make Akeega the first drug in the PARP inhibitor class for castration-sensitive prostate cancer.
Market Access One in five expressions of interest in UK regulator's pilot ... The MHRA, will be running five pilot dialogues as part of its first year exploring a real-world evidence scientific dialogue programme.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.